GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2020-03-25| Asia-PacificLicensing

Japan Grants Orphan Drug Designation to Lynparza for Germline BRCA-mutated Pancreatic Cancer

by GeneOnline
Share To

Last week, AstraZeneca announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted its PARP inhibitor Lynparza (olaparib), an orphan drug designation for the maintenance treatment of germline BRCA-mutated (gBRCAm) curatively unresectable pancreatic cancer. Lynparza is co-developed and co-commercialized with MSD Inc (MSD: known as Merck & Co., Inc. inside the US and Canada).

Among the most common forms of cancers, pancreatic cancer has the lowest survival rate and is the only major cancer that has a five-year survival rate of less than 10% in almost every country. “Japan has the fifth-highest incidence of pancreatic cancer worldwide and patients have seen limited treatment advances over the last few decades. This designation is an important step forward in bringing the first targeted medicine to biomarker-selected patients with advanced pancreatic cancer in Japan,” commented José Baselga, Executive Vice President, R&D Oncology, AstraZeneca.

Following a successful Phase III POLO trial, Lynparza was approved in the United States as a first-line maintenance treatment for patients with gBRCAm metastatic pancreatic cancer last December, with ongoing regulatory reviews in the European Union and other jurisdictions. Lynparza showed a statistically significant and clinically meaningful improvement in progression-free survival, a primary endpoint of the trial. The drug nearly doubled the time patients lived, without disease progression or death to a median of 7.4 months as compared to 3.8 months on placebo. Besides, it also performed well on other clinically relevant endpoints. The safety and tolerability profile of Lynparza in the POLO trial was in line with that observed in previous trials.

Related Article: Gilead’s Antiviral Drug, Epclusa gets FDA Nod for Pediatric Hepatitis C

References
  1. https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/lynparza-granted-orphan-drug-designation-in-japan-for-brca-mutated-metastatic-pancreatic-cancer.html
  2. https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-approved-in-the-us-as-a-1st-line-maintenance-treatment-of-germline-brca-mutated-metastatic-pancreatic-cancer-30122019.html
  3. https://clinicaltrials.gov/ct2/show/NCT02184195
  4. https://www.nejm.org/doi/full/10.1056/NEJMoa1903387

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
MediBuddy Partners with Japan’s ELECOM to Launch Smart Health IoT Devices in India
2025-02-05
$810 Million Turned Into a Rare Disease Revolution with Japan’s Nippon Shinyaku’s and USA’s REGENXBIO’s Partnership
2025-01-21
LATEST
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top